A cartridge-based assay for improved detection of multidrug-resistant Mycobacterium tuberculosis directly from sputum
Journal of Clinical Microbiology · 13.05.2026 · 64 (5)
DOI: 10.1128/jcm.01100-25 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 13.05.2026. Verfasst von Paulami Rudra und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Sputum, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Cepheid, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Tuberculosis (TB) is a global health threat complicated by increasing INH resistance (INH-R) and rifampicin resistance (RIF-R), including RIF-R due to rpoB Ile491Phe (I491F) mutations, which are not detected by current molecular resistance tests. We developed a low‐complexity automated nucleic acid amplification test MDRmDx, designed to operate on the 10-color GeneXpert instrument, which detects Mycobacterium tuberculosis (MTB), and RIF-R in both the rifampicin resistance determining region (RRDR) and the I491F allele, and INH-R due to mutations in katG , fabG1 , and the inhA promoter directly from sputum. In an analytic study, the limit of detection (LoD) for detecting MTB in sputum was 21.6 CFU/mL (95% confidence interval [CI]: 14.9–28.3) for the MDRmDx assay, versus 19.1 CFU/mL (95% CI: 14.0–24.1) for the Xpert MTB/RIF Ultra assay (Ultra). The LoD for rifampicin susceptibility (RIF-S) detection was 108.8 CFU/mL (95% CI: 77.4–140.2) versus 100.9 CFU/mL (95% CI: 67.3–134.5) for MDRmDx versus Ultra. The LoD for INH susceptibility detection was 92.2 CFU/mL (95% CI: 65.3–119.1). MDRmDx identified all rpoB mutations with a ≥0.5% global prevalence, including several not detected by Ultra. MDRmDx was 100% specific. Testing frozen sputum enriched for smear-negative, RIF-R, and INH-R samples, MDRmDx sensitivity was 91.3% (95% CI: 85.6–94.8) for MTB detection, 100% (95% CI: 95.1–100) for RIF resistance, and 98.7% (95% CI: 93.0–99.8) for INH resistance, with a specificity of 98.0% (95% CI: 89.3–99.6) for MTB detection, 93.8% (95% CI: 83.2–97.9) for RIF resistance, performance comparable to Ultra. MDRmDx specificity for INH-R was 100% (95% CI: 90.8–100). IMPORTANCE The Xpert MTB/RIF Ultra assay (Ultra) is a gold standard test for rapidly diagnosing tuberculosis (TB) as well as resistance to rifampicin directly from sputum samples. However, the Ultra assay does not detect certain rifampicin resistance mutations, which are observed clinically and cannot detect resistance to isoniazid, another key drug against TB. We modified the Ultra assay, creating a prototype MDRmDx assay designed for 10-color instruments that detects isoniazid resistance, which can be a precursor of potential rifampicin resistance and has improved ability to detect rifampicin resistance. In both analytic and retrospectively collected clinical sputum samples, we found that the MDRmDx assay performed at least as well as the Ultra assay with the additional advantage of detecting isoniazid resistance and rpoB I491F mutations with high sensitivity and specificity. The MDRmDx assay's improved performance should improve detection of drug-resistant TB and facilitate the selection of effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Cepheid Inc., Sunnyvale, California, USA.
- Frontier Science Foundation, Brookline, Massachusetts, USA.
- Foundation for Innovative New Diagnostics, Geneva, Switzerland.
- Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: Paulami Rudra, Adam Penn-Nicholson, Margaretha De Vos, Derek T Armstrong, David Alland, Soumitesh Chakravorty
Förderung
- NIAID NIH HHS
- Cepheid
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Rudra, P., Parmar, H., Daivaa, N., Tran, C., Narang, A., Singh, S., Somaiya, D., Roybardhan, S., Anwesa, R., Reiss, R., Ward, S., Penn-Nicholson, A., De Vos, M., Armstrong, D. T., Borkman, A. L., Ellner, J., Dorman, S. E., Kim, S., Yuan, L., …, & Chakravorty, S. (2026). A cartridge-based assay for improved detection of multidrug-resistant Mycobacterium tuberculosis directly from sputum. Journal of Clinical Microbiology, 64(5). https://doi.org/10.1128/jcm.01100-25
Vancouver
Rudra P, Parmar H, Daivaa N, Tran C, Narang A, Singh S, et al. A cartridge-based assay for improved detection of multidrug-resistant Mycobacterium tuberculosis directly from sputum. Journal of Clinical Microbiology. 2026;64(5). doi:10.1128/jcm.01100-25
BibTeX
@article{Rudra2026,
author = {Rudra, Paulami and Parmar, Heta and Daivaa, Naranjargal and Tran, Claire and Narang, Anshika and Singh, Simranjit and Somaiya, Dhara and Roybardhan, Samarpita and Anwesa, Ritu and Reiss, Robert and Ward, Shawn and Penn-Nicholson, Adam and De Vos, Margaretha and Armstrong, Derek T and Borkman, April L and Ellner, Jerrold and Dorman, Susan E and Kim, Soyeon and Yuan, Lin and Alland, David and Chakravorty, Soumitesh},
title = {A cartridge-based assay for improved detection of multidrug-resistant Mycobacterium tuberculosis directly from sputum},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {5},
doi = {10.1128/jcm.01100-25}
}
EUVIMED